MedTrace Logo

Effects of Simvastatin on Biomarkers

NCT01142336 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2017-07-28

Study results available
· View outcomes & findings →

Summary

A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.

Conditions

Interventions

DRUG

Simvastatin

Simvastatin 40mg qHS for 1 year

DRUG

Placebo

Placebo 1 tablet qHS for 1 year

Sponsors & Collaborators

  • Seattle Institute for Biomedical and Clinical Research

    collaborator OTHER

  • VA Puget Sound Health Care System

    collaborator FED

  • University of Washington

    lead OTHER

Principal Investigators

  • Gail Li, MD, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2015-10-31
Completion
2015-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01142336 on ClinicalTrials.gov